Blood News and Research

RSS

Beta blockers may improve effectiveness of triple negative breast cancer treatments

New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.

2 Mar 2016

Stemina developing new screening method to diagnose autism

A University of Wisconsin-Madison spinoff is screening blood samples in an effort to develop a biologically based method to diagnose autism.

2 Mar 2016

Added benefit of aflibercept not proven in myopic choroidal neovascularisation

Aflibercept (trade name: Eylea) has been approved since October 2015 for adults with impaired vision due to myopic choroidal neovascularisation.

2 Mar 2016

IDegLira injections more effective than traditional insulin injections in treating type-2 diabetes patients

More than two-thirds of all type-2 diabetes patients do not achieve good control of their disease with the first-line medication metformin combined with second-line insulin shots.

2 Mar 2016

Researchers show how increases in state and local social spending can reduce risk of dying

Income inequality and government social spending. These are hot-??button issues in this year's presidential primaries: the rich getting richer, the poor getting poorer, and the government's role in closing the gap--or not.

2 Mar 2016

New study finds link between vitamin D deficiency and aggressive prostate cancer

A new study provides a major link between low levels of vitamin D and aggressive prostate cancer. Northwestern Medicine research showed deficient vitamin D blood levels in men can predict aggressive prostate cancer identified at the time of surgery.

2 Mar 2016

MD Biosciences launches rapid assay to detect Zika virus

MD Biosciences, Inc. Clinical and Diagnostic Services Laboratory announces the release of its rapid assay to detect the virus in human blood and urine samples. The nucleic acid test can be performed in a few hours in blood, plasma, serum or urine samples.

1 Mar 2016

Preventing the spread of Zika: an interview with Professor John Oxford

The link between the Zika virus and Guillain-Barré on the one hand, and pregnancy and the virus affecting the fetus in terms of microcephaly on the other, is still not confirmed conclusively.

1 Mar 2016

Study assesses health problems related to food hypersensitivity

A study by researchers at the University of Southampton and Southampton General Hospital, is the first to assess the prevalence of two different types of food hypersensitivity and the risk factors associated with them.

1 Mar 2016

CAMH, Impel NeuroPharma partner to advance novel treatment to alleviate depression

The Centre for Addiction and Mental Health and Impel NeuroPharma have signed a licensing agreement to advance a new neuropeptide-based therapeutic approach shown to be effective in treating depression.

1 Mar 2016

Promising therapeutic strategy for relieving neuropathic pain

A specific molecule involved in maintaining pain after a nerve injury has been identified and blocked in mice by Hiroshima University researchers. These results reveal a promising therapeutic strategy for treating neuropathic pain.

1 Mar 2016

New combination treatment shows promise for treating acute myeloid leukaemia

Walter and Eliza Hall Institute researchers have discovered that the treatment of the most deadly form of blood cancer may be improved by combining two recently developed drugs.

1 Mar 2016

Scientists start clinical trial to test new prostate cancer vaccine

Oxford University scientists have started a clinical trial to test a new vaccine against prostate cancer and are looking for volunteers to take part. The first four participants have already received this experimental vaccine at the Churchill Hospital in Oxford, and the second trial site has just been opened at the Royal Hallamshire Hospital in Sheffield.

1 Mar 2016

University of Louisville cardiologist on the verge of breakthrough in predicting heart disease in women

Heart disease is the leading cause of mortality in women worldwide, including in the United States. Although deaths from cardiovascular disease (CVD) in men have declined since the 1970s, the rates of death for women have not followed.

1 Mar 2016

Rare disease day focuses on new approach to finding treatment

2,200 babies will be born in the UK on 29th February, of which 30 will die of a rare disease before they are five years old.

29 Feb 2016

On-demand liquid nitrogen generator

The Asynt CryoSyn is a unique on-demand generator (available in 10, 20, 40, 60 & 120L capacity models) which generates liquid nitrogen and nitrogen gas for industrial, medical, food and agricultural, biological and general laboratory applications.

From Asynt 29 Feb 2016

UAB researchers focus on five key areas to improve care of CVD patients

According to the Centers for Disease Control and Prevention, approximately 610,000 people die of heart disease in the United States every year — that's one in every four deaths. The impact of cardiovascular diseases is quite large.

28 Feb 2016

Sonitor Technologies announces expansion of Sonitor Sense RTLS open integration platform

Sonitor Technologies, Inc., a global leader in indoor positioning technologies, announced today the expansion of its industry-leading Sonitor Sense RTLS open integration platform.

28 Feb 2016

Single antibody could hold promise as potential treatment for human cases of EVD

A single monoclonal antibody isolated from a human survivor of Ebola virus disease (EVD) completely protected monkeys from lethal infection with the virus, according to research published in today's online edition of the journal Science.

27 Feb 2016

Researchers identify, isolate and characterize two Ebola virus neutralizing monoclonal antibodies

The Institute for Research in Biomedicine, affiliated to the Università della Svizzera italiana, and Humabs BioMed SA, a Swiss antibody therapeutics company, have identified, isolated and characterized two Ebola virus neutralizing monoclonal antibodies from the blood of a survivor of an Ebola infection.

27 Feb 2016

Blood News and Research

Beta blockers may improve effectiveness of triple negative breast cancer treatments

Stemina developing new screening method to diagnose autism

Added benefit of aflibercept not proven in myopic choroidal neovascularisation

IDegLira injections more effective than traditional insulin injections in treating type-2 diabetes patients

Researchers show how increases in state and local social spending can reduce risk of dying

New study finds link between vitamin D deficiency and aggressive prostate cancer

MD Biosciences launches rapid assay to detect Zika virus

Preventing the spread of Zika: an interview with Professor John Oxford

Study assesses health problems related to food hypersensitivity

CAMH, Impel NeuroPharma partner to advance novel treatment to alleviate depression

Promising therapeutic strategy for relieving neuropathic pain

New combination treatment shows promise for treating acute myeloid leukaemia

Scientists start clinical trial to test new prostate cancer vaccine

University of Louisville cardiologist on the verge of breakthrough in predicting heart disease in women

Rare disease day focuses on new approach to finding treatment

On-demand liquid nitrogen generator

UAB researchers focus on five key areas to improve care of CVD patients

Sonitor Technologies announces expansion of Sonitor Sense RTLS open integration platform

Single antibody could hold promise as potential treatment for human cases of EVD

Researchers identify, isolate and characterize two Ebola virus neutralizing monoclonal antibodies

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News